Some reports suggest that HCP5 could induce tumor progression in cases of follicular thyroid carcinoma and lung adenocarcinoma (51–53), while others claim that HCP5 may suppress the development of cutaneous melanoma by modulating RARRES3 expression by sponging miR-12 (42). Here, PLAAT4 is linked to thyroid gland follicular carcinoma.